Featured Press Releases

Trailblazing 3D human liver models yield accurate MASH phenotype

Trailblazing 3D human liver models yield accurate MASH phenotype

Setting a New Standard for End-to-End Traceability and Data Integrity, Waters Enhances Alliance iS HPLC System Software.

Setting a New Standard for End-to-End Traceability and Data Integrity, Waters Enhances Alliance iS HPLC System Software.

  • 18 Jun 2025

High-Performance Liquid Phase Separations and Related Techniques - Waters Corporation (NYSE: WAT)...

Biotheryx Announces First Patient Dosed in Phase 1 Clinical Trial of BTX-9341

Biotheryx Announces First Patient Dosed in Phase 1 Clinical Trial of BTX-9341

MM+M honors Petauri

MM+M honors Petauri's Nicole Lodowski as a 2025 40 Under 40 awardee

Mediar Therapeutics partners with Lilly to develop a first-in-class WISP1 antibody for idiopathic pulmonary fibrosis

Mediar Therapeutics partners with Lilly to develop a first-in-class WISP1 antibody for idiopathic pulmonary fibrosis

To Revolutionize Coronary Artery Bypass Surgery, AMT Medical Secures $25 Million in Series B Funding

To Revolutionize Coronary Artery Bypass Surgery, AMT Medical Secures $25 Million in Series B Funding

Marius Pharmaceuticals has expanded its global footprint with Health Canada’s approval of KYZATREX® (testosterone undecanoate) CIII capsules

Marius Pharmaceuticals has expanded its global footprint with Health Canada’s approval of KYZATREX® (testosterone undecanoate) CIII capsules

  • Marius Pharmaceuticals LLC
  • 13 Nov 2025
The BioTech Breakthrough Award has been granted to Asahi Kasei for the Planova™ FG1 Filter

The BioTech Breakthrough Award has been granted to Asahi Kasei for the Planova™ FG1 Filter

  • Asahi Kasei
  • 13 Nov 2025
Odyssey Therapeutics Welcomes Dennis Dean, Ph.D., as EVP, Non-Clinical Development

Odyssey Therapeutics Welcomes Dennis Dean, Ph.D., as EVP, Non-Clinical Development

  • Odyssey Therapeutics, Inc.
  • 11 Nov 2025
HanchorBio Unveils Compelling New Data at SITC 2025 Highlighting the Best-in-Class Potential of HCB101 in Advanced Cancers

HanchorBio Unveils Compelling New Data at SITC 2025 Highlighting the Best-in-Class Potential of HCB101 in Advanced Cancers

  • HanchorBio Inc.
  • 10 Nov 2025
VTAMA® (tapinarof) Cream, 1%, Demonstrates Early and Consistent Efficacy in Children Aged 2+ with Atopic Dermatitis, According to New Data

VTAMA® (tapinarof) Cream, 1%, Demonstrates Early and Consistent Efficacy in Children Aged 2+ with Atopic Dermatitis, According to New Data

  • Organon & Co.
  • 10 Nov 2025
Gilead’s Livdelzi® Shows Sustained Efficacy in PBC, Reducing ALP, Relieving Itch, and Potentially Slowing Disease Progression

Gilead’s Livdelzi® Shows Sustained Efficacy in PBC, Reducing ALP, Relieving Itch, and Potentially Slowing Disease Progression

  • Gilead Sciences, Inc.
  • 07 Nov 2025

Most Popular
November   2025
M T W T F S S
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

User Area

Discover

Engage with Us

© 2024 Pharmaceutical Era — A product of HISSM. All Rights Reserved.